Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Exploration of Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 17, 2025
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
an
emerging
and
rapidly
growing
health
problem
that
currently
affects
more
than
one-third
of
the
world
general
population
two-thirds
patients
with
obesity
or
type
2
diabetes.
MASLD
associated
one
cardio-metabolic
risk
factors
(CMRFs)
determine
complexity
its
natural
history
management.
Although
term
encompasses
a
single
disease,
each
CMRF
has
different
impact
on
MASLD,
number
overlapping
CMRFs
results
in
rate
progression
outcomes
both
systemic
disease.
Its
pathogenesis
characterized
by
insulin
resistance,
lipotoxicity
complex
cross-talk
between
liver,
adipose
tissue,
muscle,
intestine
through
release
hepatokines,
cytokines,
myokines
inflammatory
products.
The
stage
fibrosis
best
predictor
outcomes,
such
as
failure
mortality,
also
predicts
high
all-cause
mortality
In
many
cases,
development
hepatocellular
carcinoma
(HCC)
advanced
cirrhosis,
although
it
can
occur
at
all
stages
making
prevention
difficult.
increasing
very
low-density
lipoprotein
(VLDL)
secretion
chronic
low-grade
inflammation,
which
increase
cardio-vascular,
renal,
endocrine
diseases
extrahepatic
cancer.
Thus,
management
requires
holistic
approach
treatment
multispecialty
collaboration.
Currently,
diet
physical
activity
are
effective
first-line
approaches.
There
no
approved
drugs
for
apart
from
resmetirom,
percentage
cases
improves
metabolic
steatohepatitis
(MASH)
fibrosis.
We
summarize
wide
varied
recent
literature
etiopathogenetic,
clinical
therapeutic
aspects
connecting
interpreting
to
facilitate
Language: Английский
MetALD: New Perspectives on an Old Overlooked Disease
Liver International,
Journal Year:
2025,
Volume and Issue:
45(5)
Published: April 3, 2025
ABSTRACT
Metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD)
and
alcohol‐associated
(ALD)
are
the
major
contributors
to
burden
globally.
The
rise
in
these
conditions
is
linked
obesity,
type
2
diabetes,
metabolic
syndrome
increased
alcohol
consumption.
MASLD
ALD
share
risk
factors,
pathophysiology
histological
features
but
differ
their
thresholds
for
use,
definition
does
not
require
presence
of
dysfunction.
A
recent
multi‐society
consensus
overhauled
nomenclature
steatosis
introduced
term
MetALD
describe
patients
with
dysfunction
who
drink
more
than
those
less
ALD.
This
new
terminology
aims
enhance
understanding
management
poses
challenges,
such
as
need
accurately
measure
consumption
research
clinical
practice
settings.
Recent
studies
show
that
has
significant
implications
patient
management,
it
associated
mortality
risks
severe
outcomes
compared
alone.
face
progression,
cancer
cardiovascular
disease.
diagnosis
involves
adequate
quantification
use
through
standardised
questionnaires
and/or
biomarkers
well
proper
assessment
stage
progression
using
non‐invasive
tools
including
serologic
markers,
imaging,
elastography
techniques
genetic
testing.
Effective
requires
addressing
both
alcohol‐related
factors
improve
outcomes.
review
intends
provide
a
comprehensive
overview
MetALD,
covering
pathogenesis,
potential
diagnostic
approaches,
strategies
emerging
therapies.
Language: Английский
Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease: a systematic review and meta-analysis
Metabolism,
Journal Year:
2024,
Volume and Issue:
163, P. 156101 - 156101
Published: Dec. 10, 2024
Language: Английский
Life’s essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease
BMC Public Health,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Dec. 18, 2024
Language: Английский
Comment on “The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease”
Nutrition Metabolism and Cardiovascular Diseases,
Journal Year:
2024,
Volume and Issue:
34(12), P. 2844 - 2845
Published: Aug. 5, 2024
Language: Английский